DOCSLIB.ORG

Dientamoeba Fragilis, a Neglected Cause of Diarrhea, Successfully Treated with Secnidazole N

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dientamoeba Fragilis, a Neglected Cause of Diarrhea, Successfully Treated with Secnidazole N ORIGINAL ARTICLE Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole N. Girginkardes¸ler1,S¸. Cos¸kun2,I˙.Cu¨neyt Balcıog˘lu1, P. Ertan2 and U¨.Z.Ok1 1Department of Parasitology and 2Department of Pediatrics, Faculty of Medicine, Celal Bayar University, Manisa, Turkey Objective To evaluate the pathogenicity of Dientamoeba fragilis by comparing it with Giardia lamblia and to investigate the effect of a single dose of secnidazole in dienta- moebiasis. Methods Stool samples of 400 patients, admitted to the Department of Parasitology, Celal Bayar University, were examined by direct wet mount, formalin–ethyl acetate concen- tration and trichrome staining methods on three consecutive days. All cases positive for D. fragilis were treated with a single dose of secnidazole, 30 mg/kg for children, and 2 g for adults. On the seventh and fourteenth days, at the end of the treatment, stool samples were examined by the same methods, and clinical symptoms were again evaluated. Results D. fragilis and G. lamblia were detected in 35 (8.8%) and 34 (8.5%) cases, respectively. The most frequent symptoms were found to be abdominal pain and diarrhea in both infections. D. fragilis was eradicated in 34 (97.1%) patients with a single dose of secnidazole, but a second dose was necessary in one patient. Clinical symptoms disappeared in 27 (77.1%) and decreased in eight (22.9%) cases, after eradication. Conclusions These data suggested that D. fragilis is as prevalent and pathogenic as G. lamblia, and secnidazole seems to be highly effective in achieving parasitologic and clinical cure. To our knowledge, this is the first report of secnidazole being used in the treatment of dientamoebiasis. Keywords Dientamoeba fragilis, dientamoebiasis, treatment, secnidazole, epidemiology Accepted 8 March 2002 Clin Microbiol Infect 2003; 9: 110–113 trichomoniasis, amebiasis and bacterial vaginosis INTRODUCTION [5,6]. The pathogenicity of Dientamoeba fragilis has been The objective of this study was to evaluate the debated for many years. Today, clinical symptoms frequency and the pathogenicity of D. fragilis by such as abdominal pain, diarrhea, anorexia, nau- comparing it with Giardia lamblia, a better-known sea, vomiting and flatulence, which usually dis- parasite. The effect of a single dose of secnidazole appear with the elimination of the parasite, are on D. fragilis was also investigated. reported to be associated with D. fragilis [1–4]. Secnidazole, a 5-nitroimidazole, has a long half- MATERIALS AND METHODS life (approximately 17–29 h), and therefore has been used as single-dose therapy in giardiasis, Stool samples of 400 patients admitted to the Department of Parasitology, Celal Bayar Univer- sity, were investigated for intestinal parasites three Corresponding author and reprint requests: N. Girginkar- times on consecutive days. Only fresh stool speci- des¸ler, Posta Kutusu 75, Manisa, Turkey Tel: þ90 232 421 4346 mens (within 30 min of passage) were accepted, Fax: þ90 236 237 6449 and were immediately fixed in both Schaudinn’s E-mail: [email protected] fixative and 10% formalin solution. All samples ß 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases Girginkardes¸ler et al Dientamoeba fragilis treated with secnidazole 111 were examined by direct wet smear, trichrome Table 1 Clinical symptoms in cases with only D. fragilis, staining (Wheatley modification), and formalin– only G. lamblia, and no pathogenic parasite ethyl acetate concentration procedures, as pre- Only Only No pathogenic viously described [7]. D. fragilis G. lamblia parasite A questionnaire was completed for each case, (n ¼ 32) (n ¼ 30) (n ¼ 326) concerning clinical symptoms (duration and sev- Symptoms n (%) n (%) n (%) erity, if any). Stool samples were examined macro- Abdominal pain 26 (81.3) 21 (70.0) 63 (19.3) scopically. At least three soft or liquid stools per Diarrhea 23 (71.9) 23 (76.7) 37 (11.3) day are considered to constitute diarrhea, and one Anorexia 5 (15.6) 2 (6.7) 34 (10.4) formed stool a day is regarded as disappearance Fatigue 3 (9.4) 3 (10.0) 30 (9.2) Nausea 2 (6.3) 2 (6.7) 20 (6.1) of this symptom. Thirty-two cases with only D. Weight loss 1 (3.1) 2 (6.7) 16 (4.9) fragilis and three patients with both D. fragilis and Vomiting 1 (3.1) 1 (3.3) 16 (4.9) G. lamblia infections were treated with a single dose of secnidazole after dinner, 2 g for adults and 30 mg/kg for children 3–15 years of age. This smear and/or formalin–ethyl acetate concentra- treatment was ineffective in only one adult patient, tion methods were found to be effective in detect- and the same dose of secnidazole was repeated in ing 33 of 34 cases positive for G. lamblia. Of the 35 this case. On the seventh and fourteenth days, at cases positive for D. fragilis, 30 were detected in the the end of the treatment, stool samples were exam- first, three in the second, and two in the third stool ined by the same methods, and clinical symptoms examination. were again evaluated; patients did not receive any The most frequent symptoms were found to be other drugs for one week before and two weeks abdominal pain (81.3%) and diarrhea (71.9%) in after the secnidazole treatment. patients with only dientamoebiasis. These two Adult patients and parents of the children were symptoms were found to be significantly more informed about the study, and written consents frequent in patients with either only dientamoe- were obtained. The research was approved by the biasis or only giardiasis, when compared to cases Ethics Committee of the Faculty of Medicine, Celal with no pathogenic parasites (P < 0.001). Clinical Bayar University, in accordance with the Helsinki symptoms in patients with only D. fragilis infec- Declaration. tion, only G. lamblia infection and no pathogenic Comparisons were performed by chi-square parasites are shown in Table 1. tests (Yates corrected). Follow-up controls showed that D. fragilis was eradicated in 31 of 32 patients with only dienta- moebiasis, and in all three cases with both D. RESULTS fragilis and G. lamblia infection, after a single dose Four hundred cases aged between 2 and 60 years of secnidazole, but a second dose was needed for (mean ¼ 21.6 Æ 15.0) were examined for intestinal eradication of D. fragilis in one patient. Of the 32 parasites. Of these cases, 35 (8.8%) patients, aged cases with only D. fragilis infection, clinical symp- between 3 and 60 years (mean ¼ 16.9 Æ 11.7), were toms disappeared after eradication of the parasite positive for D. fragilis, and 34 (8.5%) patients, aged in 16 of 18 children (88.9%), and in nine of 14 adults between 4 and 55 years (mean ¼ 14.7 Æ 11.0), were (64.3%), while they decreased in two children positive for G. lamblia. Entamoeba histolytica, Hyme- (11.1%) and five adults (35.7%). In total, clinical nolepis nana and Taenia saginata were detected in cure and decreases in symptoms were observed in six cases (1.5%), two cases (0.5%), and one (0.3%) 25 (78.1%) and seven (21.9%) cases, respectively. case, respectively. The only pathogenic parasite No side effects were observed, except for mild was D. fragilis in 32 patients, and G. lamblia in 30 nausea in two patients. patients. Among all cases, the infection rates were found to be significantly (P < 0.05) higher in the 8– DISCUSSION 15-year age group for dientamoebiasis (14.8%), and in the 8–15- and 0–7-year age groups (13.0% Although previously considered harmless, D. fra- and 12.7%, respectively) for giardiasis. gilis has been associated with a variety of symp- D. fragilis trophozoites could only be detected by toms, mainly diarrhea and abdominal pain [1–4]. trichrome-stained slides in all cases. However, wet In this study, abdominal pain and diarrhea were ß 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 110–113 112 Clinical Microbiology and Infection, Volume 9 Number 2, February 2003 found to be significantly more frequent in patients of these treatments is between five and 21 days with only dientamoebiasis than in cases with no [2,3]. Secnidazole has the advantage of having a pathogenic parasite (P < 0.001). No significant dif- long half-life, which makes possible the single- ferences were observed between cases with only dose application [5,6]. As with other nitroimida- dientamoebiasis and those with only giardiasis for zoles, the antiprotozoal activity of secnidazole is these two symptoms. These data represent strong linked to the ferrodoxin oxidoreductase-mediated evidence for the pathogenicity of D. fragilis. reduction of the nitro group, which cannot occur The incidence of D. fragilis infection has been under aerobic conditions. Therefore, secnidazole is reported from different areas of the world in a toxic only for anaerobic organisms such as G. wide range from 1.4% to 52% [1–3, 8]. The organ- lamblia, E. histolytica, and Trichomonas vaginalis [6]. ism was reported to be the most common enter- A single dose of secnidazole was found to be opathogenic parasite in the Sultanate of Oman [9] effective for the eradication of D. fragilis in all of and in US soldiers stationed in Egypt [10]. The low our patients, except for one who needed a second incidence or absence of this organism in different identical dose. This patient was a 55-year-old male surveys may be due to the use of poor laboratory with diarrhea and abdominal pain. His symptoms recovery techniques and/or a general lack of and excretion of D. fragilis trophozoites continued knowledge concerning the parasite.
Load more

Recommended publications
  • Giardiasis Importance Giardiasis, a Gastrointestinal Disease Characterized by Acute Or Chronic Diarrhea, Is Caused by Protozoan Parasites in the Genus Giardia
    Giardiasis Importance Giardiasis, a gastrointestinal disease characterized by acute or chronic diarrhea, is caused by protozoan parasites in the genus Giardia. Giardia duodenalis is the major Giardia Enteritis, species found in mammals, and the only species known to cause illness in humans. This Lambliasis, organism is carried in the intestinal tract of many animals and people, with clinical signs Beaver Fever developing in some individuals, but many others remaining asymptomatic. In addition to diarrhea, the presence of G. duodenalis can result in malabsorption; some studies have implicated this organism in decreased growth in some infected children and Last Updated: December 2012 possibly decreased productivity in young livestock. Outbreaks are occasionally reported in people, as the result of mass exposure to contaminated water or food, or direct contact with infected individuals (e.g., in child care centers). People are considered to be the most important reservoir hosts for human giardiasis. The predominant genetic types of G. duodenalis usually differ in humans and domesticated animals (livestock and pets), and zoonotic transmission is currently thought to be of minor significance in causing human illness. Nevertheless, there is evidence that certain isolates may sometimes be shared, and some genetic types of G. duodenalis (assemblages A and B) should be considered potentially zoonotic. Etiology The protozoan genus Giardia (Family Giardiidae, order Giardiida) contains at least six species that infect animals and/or humans. In most mammals, giardiasis is caused by Giardia duodenalis, which is also called G. intestinalis. Both names are in current use, although the validity of the name G. intestinalis depends on the interpretation of the International Code of Zoological Nomenclature.
    [Show full text]
  • Drugs for Amebiais, Giardiasis, Trichomoniasis & Leishmaniasis
    Antiprotozoal drugs Drugs for amebiasis, giardiasis, trichomoniasis & leishmaniasis Edited by: H. Mirkhani, Pharm D, Ph D Dept. Pharmacology Shiraz University of Medical Sciences Contents Amebiasis, giardiasis and trichomoniasis ........................................................................................................... 2 Metronidazole ..................................................................................................................................................... 2 Iodoquinol ........................................................................................................................................................... 2 Paromomycin ...................................................................................................................................................... 3 Mechanism of Action ...................................................................................................................................... 3 Antimicrobial effects; therapeutics uses ......................................................................................................... 3 Leishmaniasis ...................................................................................................................................................... 4 Antimonial agents ............................................................................................................................................... 5 Mechanism of action and drug resistance ......................................................................................................
    [Show full text]
  • Dientamoeba Fragilis – the Most Common Intestinal Protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Helsingin yliopiston digitaalinen arkisto Research Dientamoeba fragilis – the most common intestinal protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017 Jukka-Pekka Pietilä1, Taru Meri2, Heli Siikamäki1, Elisabet Tyyni3, Anne-Marie Kerttula3, Laura Pakarinen1, T Sakari Jokiranta4,5, Anu Kantele1,6 1. Inflammation Center, Infectious Diseases, Helsinki University Hospital and Helsinki University, Helsinki, Finland 2. Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland 3. Division of Clinical Microbiology, Helsinki University Hospital, HUSLAB, Helsinki, Finland 4. Medicum, University of Helsinki, Finland 5. SYNLAB Finland, Helsinki, Finland 6. Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Finland Correspondence: Anu Kantele ([email protected]) Citation style for this article: Pietilä Jukka-Pekka, Meri Taru, Siikamäki Heli, Tyyni Elisabet, Kerttula Anne-Marie, Pakarinen Laura, Jokiranta T Sakari, Kantele Anu. Dientamoeba fragilis – the most common intestinal protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017. Euro Surveill. 2019;24(29):pii=1800546. https://doi.org/10.2807/1560- 7917.ES.2019.24.29.1800546 Article submitted on 08 Oct 2018 / accepted on 12 Apr 2019 / published on 18 Jul 2019 Background: Despite the global distribution of of Dientamoeba-like structures in formalin-fixed sam- the intestinal protozoan Dientamoeba fragilis, its ples, an approach applicable also in resource-poor clinical picture remains unclear. This results from settings. Symptoms of dientamoebiasis differ slightly underdiagnosis: microscopic screening methods from those of giardiasis; patients with distressing either lack sensitivity (wet preparation) or fail to symptoms require treatment.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 MICROBIOLOGY / VIROLOGY REVIEW(S) Division of Anti-Infective Products Clinical Microbiology Review NDA 204684 (Original NDA) Page 2 of 129 PROPOSED DOSAGE FORM AND STRENGTH: Capsules, each containing 50 mg miltefosine. ROUTE OF ADMINISTRATION AND DURATION OF TREATMENT: Impavido is recommended to be taken orally daily for 28 days with food. The number of 50 mg capsules per day will be determined by bodyweight: • 30–44 kg (66–97 lbs): one 50 mg capsule twice daily with food. • ≥45 kg (99 lbs): one 50 mg capsule three times daily with food. DISPENSED: Rx RELATED DOCUMENTS: IND 105,430 REMARKS The subject of this NDA is miltefosine for the treatment of visceral, mucosal, and cutaneous leishmaniasis. The nonclinical and clinical microbiology studies, submitted by the applicant or obtained by an independent literature search, support the activity of miltefosine against visceral, mucosal, and cutaneous leishmaniasis. A potential for development of resistance to miltefosine exists and may be due increase in drug efflux, mediated by the overexpression of the ABC transporter P-glycoprotein and/or a decrease in drug uptake by the inactivation of the miltefosine transport machinery that consists of the miltefosine transporter and its beta subunit. Mutation in the transporter gene was reported in a relapsed patient in one study. Also, some strains of L. braziliensis with intrinsic resistance to miltefosine have been identified. Such information should be included in ‘Microbiology’ subsection of the labeling. In clinical studies, the parasitological measurements at the time of screening included direct examination of aspirates/smears; at the end of treatment or follow-up visits parasitological measurements were made if clinically indicated.
    [Show full text]
  • Original Article Dientamoeba Fragilis Diagnosis by Fecal Screening
    Original Article Dientamoeba fragilis diagnosis by fecal screening: relative effectiveness of traditional techniques and molecular methods Negin Hamidi1, Ahmad Reza Meamar1, Lameh Akhlaghi1, Zahra Rampisheh2,3, Elham Razmjou1 1 Department of Medical Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran 2 Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran 3 Department of Community Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran Abstract Introduction: Dientamoeba fragilis, an intestinal trichomonad, occurs in humans with and without gastrointestinal symptoms. Its presence was investigated in individuals referred to Milad Hospital, Tehran. Methodology: In a cross-sectional study, three time-separated fecal samples were collected from 200 participants from March through June 2011. Specimens were examined using traditional techniques for detecting D. fragilis and other gastrointestinal parasites: direct smear, culture, formalin-ether concentration, and iron-hematoxylin staining. The presence of D. fragilis was determined using PCR assays targeting 5.8S rRNA or small subunit ribosomal RNA. Results: Dientamoeba fragilis, Blastocystis sp., Giardia lamblia, Entamoeba coli, and Iodamoeba butschlii were detected by one or more traditional and molecular methods, with an overall prevalence of 56.5%. Dientamoeba was not detected by direct smear or formalin-ether concentration but was identified in 1% and 5% of cases by culture and iron-hematoxylin staining, respectively. PCR amplification of SSU rRNA and 5.8S rRNA genes diagnosed D. fragilis in 6% and 13.5%, respectively. Prevalence of D. fragilis was unrelated to participant gender, age, or gastrointestinal symptoms. Conclusions: This is the first report of molecular assays to screen for D.
    [Show full text]
  • 6 Chronic Abdominal Pain in Children
    6 Chronic Abdominal Pain in Children Chronic Abdominal Pain in Children in Children Pain Abdominal Chronic Chronische buikpijn bij kinderen Carolien Gijsbers Carolien Gijsbers Carolien Chronic Abdominal Pain in Children Chronische buikpijn bij kinderen Carolien Gijsbers Promotiereeks HagaZiekenhuis Het HagaZiekenhuis van Den Haag is trots op medewerkers die fundamentele bijdragen leveren aan de wetenschap en stimuleert hen daartoe. Om die reden biedt het HagaZiekenhuis promovendi de mogelijkheid hun dissertatie te publiceren in een speciale Haga uitgave, die onderdeel is van de promotiereeks van het HagaZiekenhuis. Daarnaast kunnen promovendi in het wetenschaps­­magazine HagaScoop van het ziekenhuis aan het woord komen over hun promotieonderzoek. Chronic Abdominal Pain in Children Chronische buikpijn bij kinderen © Carolien Gijsbers 2012 Den Haag ISBN: 978-90-9027270-2 Vormgeving en opmaak De VormCompagnie, Houten Druk DR&DV Media Services, Amsterdam Printing and distribution of this thesis is supported by HagaZiekenhuis. All rights reserved. Subject to the exceptions provided for by law, no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the written consent of the author. Chronic Abdominal Pain in Children Chronische buikpijn bij kinderen Carolien Gijsbers Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.G. Schmidt en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op donderdag 20 december 2012 om 15.30 uur door Carolina Francesca Maria Gijsbers geboren te Zierikzee Promotiecommisie Promotor: Prof.dr. H.A.
    [Show full text]
  • Clinical Appendix for Parasitic Diseases Seventh Edition
    Clincal Appendix for the Seventh Edition Parasitic Diseases Despommier Griffin Gwadz Hotez Knirsch Parasites Without Borders, Inc. NY Dickson D. Despommier, Daniel O. Griffin, Robert W. Gwadz, Peter J. Hotez, Charles A. Knirsch Clinical Appendix for Parasitic Diseases Seventh Edition see full text of Parasitic Diseases Seventh Edition for references Parasites Without Borders, Inc. NY The organization and numbering of the sections of the clinical appendix is based on the full text of the seventh edition of Parasitic Diseases. Dickson D. Despommier, Ph.D. Professor Emeritus of Public Health (Parasitology) and Microbiology, The Joseph L. Mailman School of Public Health, Columbia University in the City of New York 10032, Adjunct Professor, Fordham University Daniel O. Griffin, M.D., Ph.D. CTropMed® ISTM CTH© Department of Medicine-Division of Infectious Diseases, Department of Biochemistry and Molecular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center New York, New York, NY 10032, ProHealth Care, Plainview, NY 11803. Robert W. Gwadz, Ph.D. Captain USPHS (ret), Visiting Professor, Collegium Medicum, The Jagiellonian University, Krakow, Poland, Fellow of the Hebrew University of Jerusalem, Fellow of the Ain Shams University, Cairo, Egypt, Chevalier of the Nation, Republic of Mali Peter J. Hotez, M.D., Ph.D., FASTMH, FAAP, Dean, National School of Tropical Medicine, Professor, Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, Texas Children’s Hospital Endowed Chair of Tropical Pediatrics, Co-Director, Texas Children’s Hospital Center for Vaccine Development, Baker Institute Fellow in Disease and Poverty, Rice University, University Professor, Baylor University, former United States Science Envoy Charles A.
    [Show full text]
  • Giardiasis Public Information
    Louisiana Office of Public Health Infectious Disease Epidemiology Section Phone: 1-800-256-2748 www.infectiousdisease.dhh.louisiana.gov Information on Giardiasis Public Information What is the treatment for giardiasis? What is giardiasis? Several prescription drugs are available to treat Giardia; you Giardiasis (GEE-are-DYE-uh-sis) is a diarrheal illness caused by should consult with your health care provider. Young children a very small parasite, Giardia intestinalis (also known as Giar- and pregnant women may be more likely to get dehydrated dia lamblia). Once an animal or person is infected with Giar- from diarrhea, and should drink plenty of fluids while ill. In dia, the parasite lives in the intestine and is passed in the some cases, symptoms of giardiasis will go away without any stool. The parasite is protected by an outer shell and can sur- treatment. vive outside the body and in the environment for a long time. Giardia and drinking water In the past two decades, Giardia infection has become one of the most common causes of waterborne disease (found in both Where and how does Giardia get into drinking water? drinking and recreational water) in humans in the U.S.. Giar- dia infections are more common in warmer climates, though Millions of Giardia parasites can be released in a bowel move- they may be found worldwide and in every region of the US. ment of an infected human or animal. Feces from these hu- mans or animals can get into your well through different ways How do I become infected with giardia? including sewage overflows, polluted storm water runoff, and agricultural runoff.
    [Show full text]
  • Review of the Causes and Management of Chronic Gastrointestinal Symptoms in Returned Travellers Referred to an Australian Infectious Diseases Service
    RESEARCH Review of the causes and management of chronic gastrointestinal symptoms in returned travellers referred to an Australian infectious diseases service Noha Ferrah, Karin Leder, Katherine Gibney Background t is estimated that 30–70% of the 1.1 billion overseas travellers in 2014 experienced traveller’s diarrhoea (TD). This Thirty to seventy per cent of overseas travellers experience I condition is defined as the passage of loose stools three traveller’s diarrhoea (TD), a potential cause of serious or more times in less than 24 hours during or shortly after gastrointestinal (GI) sequelae. However, there is limited returning from overseas travel.1 Diarrhoea is classified as acute evidence on the optimal management of TD. (fewer than two weeks), persistent (two to four weeks) or Objectives chronic (four weeks or longer). Acute diarrhoea accounts for the majority of TD cases, whereas persistent and chronic diarrhoea The objectives of this article are to characterise the aetiologies are less common, with estimated prevalences of 3% and 1–2% and management of returned travellers with ongoing GI respectively.1–3 Most cases of TD are caused by bacteria or symptoms referred to a specialist infectious diseases service. viruses and resolve within days, but some individuals experience persistent gastrointestinal (GI) symptoms.2 Causes of ongoing Methods GI symptoms in returned travellers may be categorised as:3 • parasitic infections, mainly Giardia and Entamoeba histolytica We conducted a retrospective medical record review of patients • unmasked GI disease such as inflammatory bowel disease referred to the Victorian Infectious Disease Service (VIDS) in 2013–15 with a history of overseas travel and GI symptoms (IBD) or malignancy present for longer than two weeks.
    [Show full text]
  • Brain-Eating Ameba Pdf Icon[PDF – 31 Pages]
    CDC Science Ambassador Workshop 2013 Lesson Plan Brain-Eating Ameba Developed by Jewel B. Moses, PhD Arcot M. Saibaba, PhD Southeast Middle School Newton High School Hopkins, South Carolina Covington, Georgia This lesson plan was developed by teachers attending the Science Ambassador Workshop. The Science Ambassador Workshop is a career workforce training for math and science teachers. The workshop is a Career Paths to Public Health activity in the Division of Scientific Education and Professional Development, Center for Surveillance, Epidemiology, and Laboratory Services, Office of Public Health Scientific Services, Centers for Disease Control and Prevention. Acknowledgements This lesson plan was developed in consultation with subject matter experts from the Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention. Jennifer Cope, MD, MPH Jonathan Yoder, MSW, MPH Medical Epidemiologist Epidemiologist Scientific and editorial review was provided by Ralph Cordell, PhD and Kelly Cordeira, MPH from Career Paths to Public Health, Division of Scientific Education and Professional Development, Center for Surveillance, Epidemiology, and Laboratory Services, Office of Public Health Scientific Services, Centers for Disease Control and Prevention. Suggested citation Centers for Disease Control and Prevention (CDC). Science Ambassador Workshop—Brain-eating Ameba. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/scienceambassador/lesson-plans/index.html. Contact Information Please send questions and comments to [email protected]. Disclaimers This lesson plan is in the public domain and may be used without restriction. Citation as to source, however, is appreciated. Links to nonfederal organizations are provided solely as a service to our users.
    [Show full text]
  • Dermatologic Manifestations of Giardiasis J Am Board Fam Pract: First Published As 10.3122/Jabfm.5.4.425 on 1 July 1992
    Dermatologic Manifestations Of Giardiasis J Am Board Fam Pract: first published as 10.3122/jabfm.5.4.425 on 1 July 1992. Downloaded from jerry T. McKnight, M.D., and Paul E. Tietze, M.D. Giardia lamblia is the most common intestinal The physical examination was remarkable only parasite in the United States and is worldwide in for an eczematous-type dermatitis with erythema, distribution.l Approximately 4 percent of stool xerosis, and several fine papular and vesicular specimens submitted to public health laboratories lesions on the extremities. The rash was con­ in this country contain Giardia cysts.2 The usual fined primarily to the trunk and extremities symptoms of acute giardiasis include diarrhea, and was located predominately on the flexor sur­ abdominal cramps, nausea, and weight loss. faces. This pattern was consistent with the previ­ Many, if not most, individuals with Giardia infec­ ous diagnosis of atopic dermatitis. The involved tion are asymptomatic. Giardiasis can be an acute skin was excoriated, and lichenification was self-limiting diarrheal illness, or it can lead to present. chronic diarrhea and malabsorption.3 Children The patient's complete blood count, chemical are affected more often than adults, and person­ analysis of serum, urinalysis, and thyroid profile to-person transmission has been documented.4,s were normal. The serum immunoglobin E(IgE) There have been reports of allergic symptoms was 48 ,....glL (20 U/mL), normal 24-240 ,....glL associated with giardiasis. This article describes a (10-100 U/mL). case of dermatitis associated with Giardia infec­ The medications were changed to fluocinonide tion and reviews dermatologic manifestations of ointment 0.05 percent twice daily and terfenadine Giardia lamblia infection.
    [Show full text]
  • LUMC Course Parasitology ESCMID Online Lecture Library © by Author
    Giardia lamblia and Dientamoeba fragilis clinical aspects, diagnostics and epidemiology © Theoby Mankauthor ESCMID Online Lecture Library LUMC course parasitology Dientamoeba © by author ESCMID Online Lecture Library LUMC course parasitology Giardia lamblia the parasite that keeps surprising © by author ESCMID Online Lecture Library LUMC course parasitology Giardia lamblia • 1681: Giardia was first observed by Anthony van Leeuwenhoek, the pioneering microscopist from Delft, The Netherlands, in his watery stools • Late 70s: Giardia was recognized as a human pathogen, based on symptoms such as malabsorption and the pathology observed in the upper part of the small intestine in patients from whom the organism was isolated (Koulda and Nohynova 1978) • 1981: The World Health© Organization by author added Giardia to its list of parasitic pathogens • ESCMID2006: Giardia was Online added to the LectureWHO “Neglected Library Disease Initiative” (Savioli et al, 2006) LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology Prevalence • Cosmopolitan • Depending on the population – Higher in case of suboptimal sanitation – Quality of drinking water – Developing countries© by author ESCMID–
    [Show full text]